K
Kai Chu
Researcher at Centers for Disease Control and Prevention
Publications - 49
Citations - 2404
Kai Chu is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Immunogenicity & Vaccination. The author has an hindex of 16, co-authored 35 publications receiving 1425 citations.
Papers
More filters
Journal ArticleDOI
Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China.
Yuemei Hu,Kangwei Xu,Weixiao Han,Kai Chu,Deyu Jiang,Jianfeng Wang,Xiaohui Tian,Zhifang Ying,Ying Zhang,Changgui Li,Fengcai Zhu +10 more
TL;DR: The new sIPV demonstrated an immunogenicity noninferior to that of the wIPV and a good safety profile in sequential vaccination with bOPV.
Posted ContentDOI
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine (KCONVAC) in Healthy Adults: Two Randomized, Double-blind, and Placebo-controlled Phase 1/2 Clinical Trials
Hong-Xing Pan,Jian-Kai Liu,Baoying Huang,Gui-Fan Li,Xian-Yun Chang,Ya-Fei Liu,Wen-Ling Wang,Kai Chu,Jialei Hu,Jingxin Li,Dan-Dan Zhu,Jing-Liang Wu,Xiao-Yu Xu,Li Zhang,Meng Wang,Wenjie Tan,Weijin Huang,Fengcai Zhu +17 more
TL;DR: In this article, the authors reported the immunogenicity and safety of a SARS-CoV-2 inactivated vaccine, KCONVAC, in healthy adults in two phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials.
Journal ArticleDOI
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.
Shiyuan Wang,Shu-Zhen Liu,Kai Chu,Yue Zhao,Fengcai Zhu,Yuemei Hu,Fan-Yue Meng,Jingxin Li,Li Luo,Jiaying Yang,Pei Liu,Jun Yu +11 more
TL;DR: The experimental QIV showed good immunogenicity and an acceptable safety profile and was found to be non-inferior to TIVs in terms of the geometric mean titers and seroconversion rates of the HI antibodies against shared strains 28 days after completion of inoculation.
Journal ArticleDOI
One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study.
Jialei Hu,Lei Jiao,Yuemei Hu,Kai Chu,Jingxin Li,Fengcai Zhu,Taishun Li,Zhiyuan Wu,Dong Wei,Fan-Yue Meng,Bingxiang Wang +10 more
TL;DR: The new plague vaccine (F1+rV) induced a robust immune response up to 12 months and showed a good safety profile in adults aged 18–55 years.
Journal ArticleDOI
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years
Kai Chu,Kangwei Xu,Rong Tang,Xiaohui Tian,Jialei Hu,Tuantuan Yang,Changgui Li,Yuemei Hu,Gang Zeng +8 more
TL;DR: The investigational IIV4 had good immunogenicity and safety, which added an influenza B protection with no increased safety concerns, and there had no significant difference in the incidence of the adverse reactions among the three groups.